Claims for Patent: 10,370,410

Summary for Patent: 10,370,410

Title:	Cancer cell-targeting peptide and use thereof
Abstract:	The present invention relates to a peptide targeting a tumor cell and use of the peptide, and more particularly, to a peptide consisting of SEQ ID NO: 1 to SEQ ID NO: 4 and specifically binding to a tumor cell, a composition including the peptide as an effective ingredient for detecting a tumor cell, a composition including the peptide as an effective ingredient for delivering a drug, and a composition including the peptide as an effective ingredient for imaging. The peptide of the present invention can be used for detection or imaging of a tumor cell in vitro and in vivo by specifically binding to a tumor cell.
Inventor(s):	Lee; Byung-Heon (Daegu, KR), Jung; Hyun-Kyung (Daegu, KR)
Assignee:	KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (Daegu, KR)
Application Number:	15/575,390
Patent Claims:	1. A peptide targeting a tumor cell, the peptide consisting of any one amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO: 2. 2. A composition for delivering a drug specifically to a tumor cell, the composition including the peptide of claim 1 as an effective ingredient. 3. The composition of claim 2, wherein the drug is any one selected from the group consisting of paclitaxel, doxorubicin, vincristine, daunorubicin, vinblastine, actinomycin-D, docetaxel, etoposide, teniposide, bisantrene, homoharringtonine, imatinib mesylate, cisplain, 5-fluouracil, adriamycin, methotrexate, busulfan, chlorambucil, cyclophosphamide, melphalan, nitrogen mustard, nitrosourea, streptokinase, urokinase, alteplase, angiotensin II inhibitor, aldosterone acceptor inhibitor, erythropoietin, N-methyl-d-aspartate (NMDA) receptor inhibitor, Lovastatin, Rapamycin, Celebrex, Marimastat, and Trocade. 4. A method of detecting a tumor cell, the method comprising: (a) mixing a peptide targeting the tumor cell with a sample, the peptide consisting of any one amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO: 4; (b) removing the peptide that is unbound or non-specifically bound; and (c) determining whether or not the peptide is bound and a binding position of the peptide. 5. The method of claim 4, wherein the tumor cell is caused by K-ras mutation. 6. The method of claim 4, wherein the peptide is labelled with one selected from a chromogenic enzyme, a radioactive isotope, a chromophore, a luminescent material, a fluorescer, a superparamagentic particle, and an ultrasuper paramagentic particle. 7. The method of claim 4, wherein tumor cell is any one selected from the group consisting of a lung tumor cell, a pancreatic cancer cell, a colorectal cancer cell, a biliary tract cancer cell, a gallbladder cancer cell, and a leukemic cell. 8. The method of claim 4, wherein the peptide is labelled with one selected from a chromogenic enzyme, a radioactive isotope, a chromophore, a luminescent material, a fluorescer, a superparamagentic particle, an ultrasuper paramagentic particle, and imaging the tumor cell. 9. A method of selectively delivering a drug to a tumor cell in a subject, comprising: preparing a peptide selectively delivering the drug to the tumor cell, the peptide is consisting of any one amino acid sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 4; and administering the peptide associated with the drug to the subject. 10. The method of claim 9, wherein the drug is any one selected from the group consisting of paclitaxel, doxorubicin, vincristine, daunorubicin, vinblastine, actinomycin-D, docetaxel, etoposide, teniposide, bisantrene, homoharringtonine, imatinib mesylate, cisplain, 5-fluouracil, adriamycin, methotrexate, busulfan, chlorambucil, cyclophosphamide, melphalan, nitrogen mustard, nitrosourea, streptokinase, urokinase, alteplase, angiotensin II inhibitor, aldosterone acceptor inhibitor, erythropoietin, N-methyl-d-aspartate (NMDA) receptor inhibitor, Lovastatin, Rapamycin, Celebrex, Ticlopin, Marimastat, and Trocade.

Details for Patent 10,370,410

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2035-05-18
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2035-05-18
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2035-05-18